GlobeNewswire: Kuros Biosciences Contains the last 10 of 45 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T20:16:29ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/06/02/2454838/0/en/Kuros-Biosciences-Completion-of-the-Acquisition-of-Checkmate-Pharmaceuticals-by-Regeneron-Pharmaceuticals-Triggers-a-5-Million-Milestone-Payment.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment2022-06-02T05:00:00Z<![CDATA[Ad-hoc announcement pursuant to Article 53 of the SIX listing rules]]>https://www.globenewswire.com/news-release/2022/02/03/2378095/0/en/Kuros-Biosciences-s-MagnetOs-Granules-Cleared-by-FDA-for-Expanded-Spinal-Indications.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications2022-02-03T06:00:00Z<![CDATA[SCHLIEREN (ZURICH), Switzerland, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that its MagnetOs Granules has been cleared by the U.S. Food and Drug Administration (FDA) for expanded indications in the spine, making it only the second-ever bone graft to achieve clearance for standalone use in the spine based on human clinical data.]]>https://www.globenewswire.com/news-release/2021/10/26/2320296/0/en/Kuros-Biosciences-Reports-Continued-Increase-in-MagnetOs-U-S-Sales.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences Reports Continued Increase in MagnetOs U.S. Sales2021-10-26T05:00:00Z<![CDATA[Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules]]>https://www.globenewswire.com/news-release/2021/09/28/2304049/0/en/Kuros-Biosciences-to-Showcase-New-MagnetOs-Products-at-NASS-2021-Annual-Meeting.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting2021-09-28T05:00:00Z<![CDATA[SCHLIEREN (ZURICH), Switzerland, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today that it will showcase new products in the MagnetOs range at the 36th Annual Meeting of the North American Spine Society (NASS), being held in Boston from September 29 to October 2, 2021.]]>https://www.globenewswire.com/news-release/2021/07/15/2263249/0/en/Kuros-to-receive-7-million-up-front-and-potentially-166-5-million-in-future-revenues-under-a-royalty-purchase-agreement-with-XOMA-related-to-Kuros-s-license-agreement-with-Checkmat.html?f=22&fvtc=4&fvtv=47504Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royalty purchase agreement with XOMA related to Kuros’s license agreement with Checkmate Pharmaceuticals2021-07-15T08:17:47Z<![CDATA[Ad hoc announcement pursuant to Article 53 of the SIX listing rules Ad hoc announcement pursuant to Article 53 of the SIX listing rules]]>https://www.globenewswire.com/news-release/2021/03/18/2195037/0/en/Kuros-Biosciences-Reports-Results-for-the-Full-Year-2020.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences Reports Results for the Full Year 20202021-03-18T06:00:00Z<![CDATA[Financial highlights]]>https://www.globenewswire.com/news-release/2021/03/10/2190033/0/en/Kuros-Biosciences-to-Present-at-Upcoming-Clinical-and-Investor-Conferences.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences to Present at Upcoming Clinical and Investor Conferences2021-03-10T06:00:00Z<![CDATA[SCHLIEREN (ZURICH), Switzerland, March 10, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN), a leader in next generation bone graft technologies and a pioneer in the emerging field of osteoimmunology, today announced that the company will present at two major European conferences in March, both to be held virtually.]]>https://www.globenewswire.com/news-release/2021/03/02/2184847/0/en/Kuros-Biosciences-Announces-MagnetOs-Sales-and-Distribution-Agreements-Across-Northern-Europe.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe2021-03-02T06:00:00Z<![CDATA[SCHLIEREN (ZURICH), Switzerland, March 02, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced that it has signed sales and distribution agreements for MagnetOs bone graft, covering the Netherlands, Switzerland, Austria, and Finland. These add to an existing agreement in the United Kingdom and Ireland.]]>https://www.globenewswire.com/news-release/2020/09/09/2091229/0/en/CORRECTING-AND-REPLACING-Kuros-Biosciences-s-Licensee-Checkmate-Pharmaceuticals-Completes-its-IPO-on-NASDAQ.html?f=22&fvtc=4&fvtv=47504CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO on NASDAQ2020-09-09T17:43:04Z<![CDATA[SCHLIEREN (ZURICH), Switzerland, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kuros Biosciences corrects gross proceeds raised in first bullet point and second paragraph to $75 million from $86.25 million. Corrected gross proceeds do not include sale of overallotment shares.]]>https://www.globenewswire.com/news-release/2020/09/09/2090569/0/en/Kuros-Biosciences-s-licensee-Checkmate-Pharmaceuticals-completes-its-IPO-on-NASDAQ.html?f=22&fvtc=4&fvtv=47504Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ2020-09-09T05:00:00Z<![CDATA[SCHLIEREN (ZURICH), Switzerland, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, notes the successful initial public offering (IPO) of Checkmate Pharmaceuticals on NASDAQ (NASDAQ: CMPI), who has licensed CMP-001, formerly known as CYT003, from Kuros.]]>